[11C]AZD0581

[11C]AZD0581 is a radiolabeled small molecule antagonist of the C-C chemokine receptor type 9 (CCR9), developed by AstraZeneca as a positron emission tomography (PET) radiotracer. CCR9 is a G protein-coupled receptor predominantly expressed on gut-homing T lymphocytes; its interaction with the ligand CCL25 (TECK) mediates the migration of these cells to the intestinal mucosa. In Crohn's disease, this pathway is a key driver of chronic inflammation. [11C]AZD0581 was utilized in clinical studies to visualize and quantify CCR9 expression in the gastrointestinal tract of patients, aiming to provide a non-invasive method for assessing disease activity and target engagement of CCR9-targeted therapeutics. While the tracer demonstrated the ability to image CCR9-positive cells in the gut, the clinical development of the parent compound AZD0581 for the treatment of Crohn's disease was ultimately discontinued following early-phase evaluation.

Other names

CCR9 antagonist radiotracerCCR-9 antagonist radiotracerCCR 9 antagonist radiotracer11C-AZD0581AZD0581 PET tracerAZD-0581 PET tracerAZD 0581 PET tracer